CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Merck Sharp & Dohme Corp. vs. GlaxoSmithKline Biologicals SA

๐Ÿ“ก 5G SEP โ€ข ETSI Declared

Explore the PTAB proceeding IPR2019-00230 filed by Merck Sharp & Dohme Corp. on 2018-11-07. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2019-00230

Filing Date

2018-11-07

Accorded Filing Date

2018-11-07

Institution Decision Date

2019-05-09

Last Modified Date

2022-05-10

Proceeding Type

IPR

Termination Date

2019-06-12

Trial Status

Terminated-Settled

Parties & Counsel

Petitioner

Patent Owner / Respondent

Patent Information

1 Patent Involved
Respondent Application Number 13500244
Respondent Patent Number 9422345
Legal Expiration Date
2033-09-05 Active (6.8 yrs remaining)
Patent Term Adjustment (PTA) +1064 Days Awarded
Injunction Viability (35 U.S.C. ยง 283) Active Threat
Respondent Inventor Normand Blais et al
Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Tribunal & APJ Panel Intelligence

Board Intelligence

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Decisions Rendered

1 Total

Proceeding Status

Terminated-Settled

Administrative Patent Judges (APJ Panel)

Panel assignment tracked upon institution decision entry

Board Decisions & Rulings (1)

Termination 2019-06-12
Judgment Granting Joint Motion to Terminate Proceedings Due to Settlement after Institution and Granting Joint Motion to Treat Settlement Agreement as Business Confidential Information
37 CFR 42.5, 37 CFR 42.72, 37 CFR 42.74, 35 USC 317

Address and Attorney/Agent Information

11 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name GLAXOSMITHKLINE - Global Patents UP4110
Customer Number 23347
Address 1250 South Collegeville Road, Collegeville, PA, 19426, UNITED STATES

Attorney / Agent Information

Reg # Name Phone
36689 Nora Stein +1 484-949-5801
40820 Robert Smith +1 980-219-9608
45582 John Young +1 919-483-8160
45941 Eric Kron +1 919-483-8961
47115 J. Strickland +1 919-483-9024
48708 Joseph Schuller +1 202-617-7187
51491 Alice Bradney +1 919-450-8851
58542 William Long +1 484-919-7863

Global Patent Family Cross-Litigation Radar

CasLoc 360ยฐ Radar 4 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

๐Ÿ‡บ๐Ÿ‡ธ
U.S. District Courts Counterparts in force
๐Ÿ›๏ธ
USPTO PTAB Trials 4 proceedings
๐Ÿ‡ช๐Ÿ‡บ
Unified Patent Court (UPC) Counterparts in force
๐Ÿ‡ฉ๐Ÿ‡ช
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (4): GB ๐Ÿ‡บ๐Ÿ‡ธ US ๐ŸŒ PCT
Parallel Proceedings Across Jurisdictions (4 found):
PTAB: 4
USPTO PTAB Trial 2019-08-09
IPR2019-01478

Pfenex Inc. v. GlaxoSmithKline Biologicals SA

Asserted Patent
Status: Institution Denied
USPTO PTAB Trial 2019-05-06
IPR2019-01027

Pfenex Inc. v. GlaxoSmithKline Biologicals SA

Asserted Patent
Status: Institution Denied
USPTO PTAB Trial 2019-05-06
IPR2019-01028

Pfenex Inc. v. GlaxoSmithKline Biologicals SA

Asserted Patent
Status: Terminated-Settled
USPTO PTAB Trial 2018-11-07
IPR2019-00241

Merck Sharp & Dohme Corp. v. GlaxoSmithKline Biologicals SA

Asserted Patent
Status: Terminated-Settled
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Standard Essential Patent (SEP) & FRAND Intelligence

5G SEP โ€ข ETSI Declared High-Probability SEP Action

Essential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation

FRAND Encumbered
Essential Standard 4G / 5G LTE Generation: 5G
Standard Setting Org (SSO) ETSI / 3GPP Essential specification under ETSI / 3GPP governance
FRAND Commitment Committed Fair, Reasonable & Non-Discrim.
Known Patent Pools Avanci / Sisvel / Via Licensing Coverage Applicable Declarant: Sharp

Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)

Permanent Injunction Restricted

Asserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.

โœ“ Patentee bound by SSO IPR Policy (ETSI Annex 6 / IEEE Patent Policy).
โœ“ Right to demand global FRAND portfolio determination.
โœ“ Non-discrimination defense: check licensing terms offered to competing implementers.

Proceeding Documents

92
14

Judgment Granting Joint Motion to Terminate Proceedings Due to Settlement after Institution and Granting Joint Motion to Treat Settlement Agreement as Business Confidential Information Paper

2019-06-12 FILING PARTY: BOARD
13

Joint Request to File Settlement Materials Paper

2019-05-29 FILING PARTY: PETITIONER
12

Joint Motion to Terminate IPRs Paper

2019-05-29 FILING PARTY: PETITIONER
10

Petitioner's Objections to Evidence Submitted by Patent Owner During a Preliminary Proceeding Paper

2019-05-23 FILING PARTY: PETITIONER
11

Patent Owner's Objections to Petitioner's Evidence Paper

2019-05-23 FILING PARTY: PATENT OWN

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc